Analysts’ Top Healthcare Picks: ATRS, DRRX

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (NASDAQ: ATRS) and Durect Corp (NASDAQ: DRRX) with bullish sentiments.

Antares Pharma (NASDAQ: ATRS)

Antares Pharma (NASDAQ: ATRS) received a Buy rating and a $5 price target from H.C. Wainwright analyst Corey Davis today. The company’s shares closed yesterday at $3.01, close to its 52-week high of $3.24.

According to TipRanks.com, Davis is a 3-star analyst with an average return of 3.1% and a 47.5% success rate. Davis covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Aquinox Pharmaceuticals, and Infotek Pharmaceuticals.

Antares Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $4.65.

Durect Corp (NASDAQ: DRRX)

H.C. Wainwright analyst Ed Arce reiterated a Buy rating on Durect Corp (NASDAQ: DRRX) today and set a price target of $3. The company’s shares closed yesterday at $1.48.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 25.2% and a 48.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics Inc, and Sucampo Pharmaceuticals.

Durect Corp has an analyst consensus of Moderate Buy, with a price target consensus of $3.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.